1. Introduction
===============

Alzheimer\'s disease (AD) is an age-related neurodegenerative disease characterized by progressive memory and neuronal loss combined with cognitive impairment.^\[[@R1]\]^ It is the most common neurodegenerative disease in the world.^\[[@R2]\]^ Mild cognitive impairment (MCI) is considered to be a prodromal phase (preclinical stage) of AD.^\[[@R3]\]^ The early definition of MCI refers to the progressive memory impairment and cognitive impairment similar to AD, However, it retains the overall cognitive function and activities of daily living.^\[[@R4],[@R5]\]^ Mild cognitive impairment and AD are neurodegenerative diseases associated with aging. The major clinical features of both are progressive memory loss and progressive cognitive loss.^\[[@R6],[@R7]\]^ However, the pathogenesis has not been well elucidated, which limits its pharmacological treatment.^\[[@R8]\]^ MCI patients are at high risk of developing AD. Studies have shown that the annual conversion rate of MCI to AD is about 8.3% to 28%,^\[[@R5],[@R9]\]^ and the rate of conversion to AD increases with age and course of disease, while the rate of normal elderly people is only 1% to 2%.^\[[@R10]\]^

With the rapid development of the global economy and the improvement of the public basic health conditions, the average life span of human beings is increasing, which will undoubtedly lead to the aging of the world population. It is expected that there will be global MCI, AD and AD-related dementia pandemics.^\[[@R11],[@R12]\]^ According to the data released by Alzheimer\'s Disease International in 2018, as of 2015, there were about 50 million AD patients in the world, and the number will reach about 152 million in 2050. The total cost of treatment for Alzheimer\'s patients worldwide is as high as \$1 trillion in 2018, and by 2030, this number will double.^\[[@R2]\]^

So far, the clinical treatment of AD is mainly western medicine according to the clinical guidelines. The US Food and Drug Administration has approved five drugs, including donepezil, rivastigmine, galantamine, and tacrine (four acetyl cholinesterase inhibitors) and memantine (an N-methyl-D-aspartate receptor antagonist) for the treatment of AD.^\[[@R13],[@R14]\]^ However, these drugs can only alleviate the symptoms of learning, memory, and cognitive impairment. No drugs have been found to completely cure AD or improve the life quality of patients. Moreover, chemical drugs have many shortcomings certain adverse reactions, such as large side effects, high price, poor compliance, and unclear efficacy. Due to the limitations of the existing drugs, the need for clinical intervention in patients with AD and MCI is particularly important and urgent, so it is of great significance to find a breakthrough non-pharmacological therapy.^\[[@R15],[@R16]\]^

As a non-pharmacological treatment method of traditional Chinese medicine, acupuncture has been applied to the treatment of dementia since ancient times. Moreover, acupuncture has advantages such as safety, convenience, very few side effects, and low price. A large number of clinical studies suggest that acupuncture can significantly improve cognitive function and improve patients' quality of life.^\[[@R17]--[@R19]\]^ In recent years, more and more animal researches have been made to explore the mechanism of acupuncture treatment of AD and a large number of studies have confirmed that acupuncture can improve the cognitive function of AD model animals, providing experimental and theoretical basis for the future clinical application of acupuncture in the treatment of AD and MCI.^\[[@R20]--[@R23]\]^ However, there is still remaining no systematic review to present evidence of effectiveness of acupuncture for reducing cognitive dysfunction in AD transgenic mouse models. Consequently, our study is performed to provide a systematic review in terms of the efficacy of acupuncture in the treatment of AD and MCI in transgenic mouse.

2. Methods
==========

2.1. Study registration
-----------------------

This systematic review protocol has been registered on PROSPTERO ([www.crd.york.ac.uk/prospero/](http://www.crd.york.ac.uk/prospero/)) with number CRD42019142985. The protocol follows a checklist of the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES) with minor modifications.^\[[@R22]\]^ We will describe the changes in our full review.

2.2. Inclusion criteria for study selection
-------------------------------------------

### 2.2.1. Types of studies

Only the controlled studies with a separate control group will be included. Languages including English and Chinese, and Chinese will be translated into English in the final version. No publication dates limitations.

### 2.2.2. Types of participants

All transgenic mouse models with MCI or AD (all sexes).

### 2.2.3. Types of interventions

All transgenic mouse models with MCI or AD which used acupuncture and related techniques alone as intervention, such as acupuncture, electroacupuncture, moxibustion, acupressure, cupping, acupoint injection, laser acupuncture, auricular needle, scalp needle, acupoint bloodletting therapy, fire needling, intradermal needling and acupoint catgut embedding acupressure, etc. All timings, frequencies and duration of treatment are eligible for inclusion.

### 2.2.4. Types of outcome measures

Morris water maze, passive avoidance test, Y-maze test and other behavior test which is commonly used to evaluate spatial learning and memory ability in mouse models.

2.3. Exclusion criteria
-----------------------

1.  Animals other than transgenic mouse.

2.  Vivo, in vitro, and in silico models.

3.  Case studies, cross-over studies, studies without a separate control group.

4.  Cognitive dysfunction in mice is derived from other diseases, not MCI or AD.

5.  The intervention was acupuncture combined with Chinese herbal medicine or western medicine or any other type of treatment.

6.  The intervention was aimed to compare different acupuncture techniques or different acupoints.

7.  No relevant outcomes reported.

8.  Duplicate publications.

2.4. Search methods for identification of studies
-------------------------------------------------

### 2.4.1. Electronic searches

We will search the following electronic databases from inception to July 2019: PubMed, Web of Science, Embase, PsycINFO, as well as the Chinese databases such as Chinese Biomedicine Literature (CBM), Chinese Medical Current Content (CMCC), Chinese Scientific Journal Database (VIP), WanFang Database, and China National Knowledge Infrastructure (CNKI). Databases were searched from their inception dates to July 2019. No language restrictions were applied in the search strategy.

### 2.4.2. Searching strategy

The search strategy for Pubmed is listed in Table [1](#T1){ref-type="table"}, which includes all search terms, and other searches will be conducted based on these results. This search strategy will be modified as required for other electronic databases.

###### 

PubMed search strategy.

![](medi-98-e17557-g001)

2.5. Data collection and analysis
---------------------------------

### 2.5.1. Selection of studies

To select studies for this review, two researchers (Yang Yang and Shaowen Hu) evaluate the titles and abstracts of identified articles. Then, the two researchers download the full text of the articles to review the study design and methodology for studies that used acupuncture and its related techniques as intervention and measure cognitive problems in transgenic mouse. Each researcher will make decision on every research independently. Disagreements among the researchers will be resolved by a discussion. If they do not reach the same decision, the concerned articles will be discussed with a third author (Chunzhi Tang) until the consensus is reached. The whole procedure of study selection will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow chart in Figure [1](#F1){ref-type="fig"}.

![Flowchart of study selection.](medi-98-e17557-g002){#F1}

### 2.5.2. Data extraction and management

Two researchers (Yang Yang and Shaowen Hu) will be responsible for data extraction. They must agree on the eligibility criteria. If the data is presented graphically, the researchers will attempt to obtain the numerical values from the trial authors; if the value is not available, we will use the digital ruler software to estimate the values in the graph. If we are unable to obtain complete data, then we will exclude the test of missing data from the data synthesis. If there are any disagreements, the authors will discuss with each other and ask the third author (T.CZ.) to resolve the differences until a consensus is reached.

### 2.5.3. Assessment of risk of bias and reporting of study quality

The quality of each study was assessed independently by use of the CAMARADES checklist, they will get a score from 0 to 10. Two reviewers (Yang Yang, Shaowen Hu) independently extracted the data and assessed the quality of each study. Disagreements were resolved through discussion.

### 2.5.4. Measurement of treatment effect

We will use the relative risk with 95% confidence intervals (CIs) to analyze the effects of treatment for dichotomous outcomes. For continuous outcomes, we will use the weighted mean difference or the standard mean difference (SMD) with 95% CIs. The SMD is equal to the difference in the mean outcome between the groups divided by the standard deviation of the outcomes among the participants, which is reported in units of standard deviation and allows data measured on different scales to be merged. Negative SMD effect sizes indicate a positive efficacy for memory acquisition, the other is the opposite.

### 2.5.5. Unit of analysis

For studies comparing different type, timing or duration of acupuncture treatment to a single control group, the data from all experimental groups will be pooled to compare with the control group. For crossover trials, we will extract the data of first study period to avoid the unit of analysis issue.

### 2.5.6. Dealing with missing data

If the extractions are unclear or incomplete, we will try to contact the corresponding author or first author to obtain the data. If the data cannot be obtained, the article will be excluded.

### 2.5.7. Assessment of heterogeneity

Both the *χ*^2^ test and the *I*^2^ statistic will be used for the assessment of heterogeneity between the studies in effect measures. We will consider an *I*^2^ value \> 50% suggests unacceptable heterogeneity.

### 2.5.8. Assessment of reporting bias

If there are more than 10 studies included in this meta-analysis, the funnel plot is drawn to detect if there is a publication bias; if \<10 studies are included, there is no need to draw a funnel plot, and it is not necessary to check the asymmetry of the funnel plot.

### 2.5.9. Data synthesis

The meta-analysis will be performed with RevMan 5.3 software. *P* values of \< .05 were considered statistically significant. We will select the fixed-effects model (*I*^2^ \< 50%) or random-effects model (*I*^2^≥50%) based on the heterogeneity levels of the included studies. Sensitivity analysis and subgroup analysis will also be performed to find out any possible reasons that may cause the heterogeneity. However, we will not accept the data in meta-analysis if significant heterogeneity (*I*^2^ \> 75%) still exists after sensitivity analysis and subgroup analysis.

### 2.5.10. Subgroup analysis

Subgroup analyses will also be used to identify associations between relevant study characteristics, such as different type of transgenic mouse, sex, anesthetic method, type and duration of acupuncture, and study quality, when substantial heterogeneity existed.

### 2.5.11. Sensitivity analysis

After conducting a quality assessment of the included studies, we will conduct a sensitivity analysis if there are studies of low quality. Sensitivity analysis will also be performed when heterogeneity testing suggests significant heterogeneity between studies.

3. Discussion
=============

AD is an age-related neurodegenerative disease. The prevalence of AD doubles every 5 years in people aged 65 to 85, from about 1% to 2% at age 65 to more than 30% to 50% at age 85.^\[[@R24]\]^ And these are only the cases that are clearly diagnosed by doctors. In developed countries, only 50% of AD patients are definitely diagnosed, and in developing countries, even \<10%.^\[[@R4]\]^

Clinically, cognitive impairment, learning and memory dysfunction, and mental disorders are the main clinical manifestations and diagnostic indicators in patients with AD and MCI. Therefore, animal experiments are often conducted to test whether the behavioral changes of animal models with cognitive dysfunction are consistent with clinical symptoms in human, so as to evaluate the reliability of animal models and the effectiveness of therapeutic intervention methods. In recent years, experimental studies on cognitive impairment using transgenic mouse have been increasing. Also, and transgenic mouse has been recognized as the animal model closest to AD.^\[[@R25],[@R26]\]^

Acupuncture is frequently used in China and believed to affect memory and learning in AD and MCI. There are numerous clinical studies demonstrate that acupuncture has positive effect in improving the cognitive function of MCI and AD. But the underlying mechanism of acupuncture in treating cognitive impairment has not yet been found. So there is more and more animal studies conducted to explore the underlying mechanism. Currently, no systematic review and meta-analysis have been conducted regarding the effectiveness to improve cognitive function of acupuncture treatment for AD and MCI in transgenic mouse models. Then we perform a meta-analysis of published AD transgenic mouse studies which used acupuncture as intervention to improve cognitive performance to examine the potential correlation between acupuncture and cognitive function caused by MCI or AD.
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